Literature DB >> 11371403

Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.

P J Dennesen1, A J van der Ven, A G Kessels, G Ramsay, M J Bonten.   

Abstract

Although recommended durations of antimicrobial therapy for ventilator-associated pneumonia (VAP) range from 7 to 21 d, these are not based on prospective studies and little is known about the resolution of symptoms after start of antibiotics. Resolution of these symptoms was investigated in 27 patients. VAP was diagnosed on clinical, radiographic, and microbiological criteria, including quantitative cultures of bronchoalveolar lavage. All patients received appropriate antibiotic therapy. Highest temperatures, leukocyte counts, Pa(O(2))/FI(O(2)) ratios, and semiquantitative cultures of endotracheal aspirates were recorded from start of therapy until Day 14. Resolution was defined as the first day that these parameters fulfilled the following definition: temperature < or = 38 degrees C, leukocytes < or = 10 x 10(9)/L, Pa(O(2))/FI(O(2)) ratio > or = 25 kPa, and no or +1 of bacterial growth of etiologic pathogens in cultures of endotracheal aspirate. VAP was caused by Enterobacteriaceae (n = 14), P. aeruginosa (n = 7), S. aureus (n = 6), H. influenzae (n = 3), and S. pneumoniae (n = 1). H. influenzae and S. pneumoniae were eradicated from tracheal aspirates, whereas Enterobacteriaceae, S. aureus, and P. aeruginosa persisted, despite in vitro susceptibility to antibiotics administered. Significant improvements were observed for all clinical parameters, most apparently within the first 6 d after start of antibiotics. Newly acquired colonization, especially with P. aeruginosa and Enterobacteriaceae, occurred in the second week of therapy. Six patients developed a recurrent episode of VAP, four of them with P. aeruginosa. Clinical responses to therapy for VAP occur within the first 6 d of therapy, endotracheal colonization with Gram-negative bacteria persists despite susceptibility to therapy, and acquired colonization usually occurs in the second week of therapy and frequently precedes a recurrent episode.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371403     DOI: 10.1164/ajrccm.163.6.2007020

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  46 in total

Review 1.  Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia.

Authors:  Victor L Yu; Nina Singh
Journal:  Intensive Care Med       Date:  2004-02-28       Impact factor: 17.440

2.  Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.

Authors:  Besu F Teshome; Scott Martin Vouri; Nicholas Hampton; Marin H Kollef; Scott T Micek
Journal:  Pharmacotherapy       Date:  2019-01-07       Impact factor: 4.705

3.  Direct examination and cultures of bronchoalveolar lavage in pneumonia diagnosis: a comparative experimental study.

Authors:  Nilton Brandão da Silva; Lucas Martins; Frederico Martins; José Anflor; Tiago Tonietto; Cristiano Koefender; Paulo G Cardoso; José Moreira
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

4.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

5.  Bronchoalveolar lavage for VAP diagnosis: patients must be sampled before any change of antimicrobial therapy.

Authors:  Jean-François Timsit
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

6.  What can be expected from antimicrobial de-escalation in the critically ill?

Authors:  Marin H Kollef
Journal:  Intensive Care Med       Date:  2013-11-19       Impact factor: 17.440

7.  Current problems in the diagnosis and treatment of hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Masahiro Sakaguchi; Nobuaki Shime; Naohisa Fujita; Sakiko Fujiki; Satoru Hashimoto
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

8.  Severe hospital-acquired pneumonia: a review for clinicians.

Authors:  John Dallas; Marin Kollef
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

Review 9.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 10.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.